Stemline Therapeutics

Ticker STML

Exchange NASDAQ More
Industry Biotechnology More
Sector Healthcare More

11-50 Employees
Based in New York City, New York

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics. Stemline is developing three clinical stage product candidates, SL-401, SL-701, and SL-801. A potentially pivotal Phase 2 trial with SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R; CD123) present on a wide range of hematologic cancers, is currently…More

Visit website

Social Media Links

REPORT RATINGS

4.8 / 5.0 (130)

Stemline Therapeutics reports have an aggregate usefulness score of 4.8 based on 130 reviews.

Stemline Therapeutics

Most Recent Annual Report

MOST RECENT 2019 Annual Report and Form 10K

View PDF View Form 10K (HTML)

Stemline Therapeutics does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Please fill out the form below and click "Place Order" to complete your order.